/** Title: Akums Q1 FY27: CDMO Momentum Lifts Margins, While Cosmetics Adds a New Angle */

Akums Q1 FY27: CDMO Momentum Lifts Margins, While Cosmetics Adds a New Angle

Akums Drugs and Pharmaceuticals opened FY27 with a quarter that was stronger on profitability than on pure topline acceleration. Consolidated operating revenue for Q1 FY27 stood at INR 1,167 crore, up 13.9% year on year and broadly stable sequentially versus Q4 FY26. What stood out was the step-up in operating leverage. EBITDA rose 35.4% year on year to INR 175 crore, taking EBITDA margin to 15.0% from 12.6% a year ago. PAT increased 56.1% year on year to INR 101 crore.

Management attributed the performance largely to the CDMO segment, where double-digit volume growth and improved API pricing supported both growth and margins. The quarter also showed early signs of improvement in the API segment’s profitability profile, even though it remains loss-making. In parallel, the company announced the acquisition of Oriflame India’s manufacturing business, expanding its manufacturing footprint in cosmetics and wellness and adding a new, adjacent category to its niche-formulations strategy.

Q1 performance: stronger margins, steady revenue base

The income statement reflects a quarter where gross margin improved and operating leverage began to show through. Gross margin expanded to 44.7% from 43.2% in Q1 FY26. Other expenses were contained, and management indicated the improvement was driven by higher-value products and better contribution from CDMO and improved API gross margins.

From a segment standpoint, CDMO continues to dominate the business. It contributed 82.6% of revenue in the quarter. Domestic branded formulations grew mid-single digit, but margins were pressured due to an increase in field force strength. International branded formulations had a muted quarter. Trade generics stayed around break-even at the EBITDA level, and API losses narrowed.

Segment lens: CDMO drives growth, branded invests, API narrows losses

The CDMO segment delivered Q1 FY27 revenue of INR 964 crore, up 18.6% year on year. EBITDA for CDMO rose to INR 163 crore, with the segment margin shown at 17.0% in Q1 FY27 versus 14.7% in Q1 FY26. Management pointed to healthy volume growth and improving capacity utilization, which was cited at 50% during the quarter.

Management also discussed the role of API prices in the quarter. They noted that API prices had increased in Q1 after declines over the preceding three quarters, while also acknowledging that volatility remains high going into Q2. On the call, management reiterated their annual EBITDA margin range guidance of 14% to 15% and indicated the company could lean toward the upper end, supported by a strong Q1.

Domestic branded formulations, under Akumentis, reported revenue of INR 115 crore, up 7.3% year on year and 12.9% quarter on quarter. EBITDA, however, fell to INR 12 crore, with the margin dropping to 10.3% in Q1 FY27 versus 14.7% in Q1 FY26. Management linked the margin pressure to a deliberate expansion in field force strength. They indicated around 200 employees were added to expand into adjacent territories and improve prescription reach. Management expects improved performance from this segment from Q3 onwards as productivity ramps.

International branded formulations, referred to as Unosource in the concall, recorded revenue of INR 35 crore, down 1.5% year on year. EBITDA was INR 6.9 crore, with margins lower than the previous quarters. Management called the quarter muted but indicated the business should return to growth from Q2 and Q3 onwards. The stated approach is to focus on a smaller set of priority markets within its broader 60-plus geography footprint and build a portfolio around niche and first-to-launch products.

The API segment reported revenue of INR 32 crore, down 29.7% year on year, and EBITDA of minus INR 4 crore. While still negative, losses narrowed meaningfully compared with minus INR 6 crore in Q1 FY26 and minus INR 12 crore in Q4 FY26. Management attributed the improvement to a higher share of non-cepha products, which improved gross margins, and reiterated a timeline to become monthly EBITDA positive by February to March, with positive profit contribution expected in the following year.

Trade generics revenue came in at INR 21 crore. The segment remained around break-even on EBITDA, with INR 0.1 crore in Q1 FY27, following a similar break-even trend in the prior quarter.

Strategy and capital allocation: cosmetics acquisition and capacity planning

A key corporate action during the quarter was the acquisition of Oriflame India’s manufacturing business, announced on July 23. The transaction value was INR 56 crore and includes two manufacturing facilities in Noida and Roorkee, plus a leased warehouse in Noida.

Management positioned the acquisition as aligned with Akums’ strategy of tapping niche formulations and improving margin profile. The company already operates a dedicated cosmetics plant and highlighted that recent interest has driven high utilization in that facility. The newly acquired units add capacity in skincare, personal care and hair care products, and expand into color cosmetics. They also add wellness manufacturing capability through soft gels, tablets and protein powders. Management stated manufacturing of Oriflame products will continue, alongside plans to onboard other CDMO customers at these sites.

On capacity, management reiterated its approach of maintaining spare capacity to respond to sudden volume upticks. They indicated that peak utilization can move toward about 55% to 60% over time. Management also mentioned the company is setting up an additional facility in Baddi and separately referred to added oral tablet capacities expected to go live by the end of the year, though they did not disclose capex numbers.

The balance sheet remains a key feature of the story. Management stated the company has a net cash surplus of INR 1,616 crore. The CFO added that about 98% of the cash is parked in fixed deposits with nationalised banks. On use of cash, management kept the stance opportunistic and value-accretive, stating they would pursue acquisitions where there are clear synergies and business rationale.

Closing take: strong CDMO quarter, execution test shifts to growth investments

Q1 FY27 reinforced Akums’ positioning as a CDMO-led manufacturer with operating leverage benefits when volume momentum sustains. The quarter delivered a meaningful improvement in profitability, supported by gross margin expansion and better segment mix, while the company maintained its annual margin guidance range.

The next set of investor focus points is likely to be execution-driven. Domestic branded formulations need to convert the added field force into sustained productivity without prolonged margin drag. International branded formulations need to demonstrate the return to growth that management expects from Q2 and Q3. And the API segment remains a turnaround in progress, with management’s stated goal of monthly EBITDA positivity by February to March serving as an important milestone.

Alongside these, the Oriflame acquisition adds an adjacent growth vector in cosmetics and wellness manufacturing, consistent with management’s stated strategy of niche capabilities. With a strong net cash position, Akums has financial flexibility, but the outcomes will depend on disciplined execution across both core CDMO and the newer capability expansions.